Press release 📈 Stocks 🌍 United States

Ichnos Glenmark Innovation Files FDA IND Application for ISB 2301

Ichnos Glenmark Innovation has filed an IND application with the FDA for its pentaspecific immunocell activator ISB 2301, with a Phase-1 clinical trial for solid tumors targeted for 2027.

🕐 1 min read

1 assets impacted. Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: GLENMARK.NS → 2/10 (40% confidence).

📊 Affected Assets (1)

GLENMARK.NS
Neutral 🤖 40%
🗓️ Long-term 🌍 IN ✨ Inferred

Ichnos Glenmark Innovation filed an IND application with the FDA for ISB 2301, a first-in-class pentaspecific immunocell activator, and plans a Phase-1 study in solid tumours in 2027. This is an early, routine regulatory step, not an approval or clinical result, so it does not materially change the outlook for the listed parent in the coming days to weeks.

🎯 Key Takeaways

  • IGI submitted an IND application to the FDA for ISB 2301, a pentaspecific molecule targeting three tumor-associated antigens.
  • The candidate is designed to activate both T-cells and NK-cells to address the heterogeneity of solid tumors.
  • IGI plans to launch a Phase-1 clinical trial evaluating ISB 2301 in patients with solid tumors in 2027.

📝 Executive Summary

Ichnos Glenmark Innovation (IGI) has submitted an Investigational New Drug (IND) application to the U.S. FDA for ISB 2301. This first-in-class pentaspecific immunocell activator is designed to target three tumor-associated antigens while activating both T-cells and NK-cells to combat solid tumors. The company plans to initiate a Phase-1 clinical trial for the candidate in 2027.